Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 10/20 | 0.46 |
| ▸ | TMPRSS6 | Q8IU80 | 4/20 | 0.46 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14999923 | 0.86 | MAPT (0.46) | F2LARS1LMNA | |
| SCHEMBL14999932 | 0.85 | LARS1 (0.47) | F2LARS1LMNA | |
| SCHEMBL3090331 | 0.85 | LARS1 (0.47) | F2LARS1LMNA | |
| SCHEMBL3090750 | 0.85 | LARS1 (0.45) | F2LARS1LMNA | |
| SCHEMBL3093901 | 0.85 | MMP9 (0.46) | F2LARS1PLGLMNA | |
| SCHEMBL3102970 | 0.85 | MMP9 (0.46) | F2LARS1PLGLMNA | |
| Trifluoroacetic Acid SCHEMBL3100526 | 0.84 | F2 (0.39) | F2LARS1PLG | |
| SCHEMBL3090735 | 0.84 | F2 (0.48) | F2LARS1PLG | |
| SCHEMBL3085973 | 0.84 | LARS1 (0.53) | F2LARS1PLGLMNA | |
| SCHEMBL3103564 | 0.84 | KAT6A (0.44) | F2LARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | F2 4128/4885TMPRSS6 38/4885LARS1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.